{
  "docId": "019de071-b48b-74ad-8fcb-69ba4c0494fb",
  "docSlug": "4047dd7a7e0f28ca31128b58ef648c55",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 39 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 39,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes a stacked bar chart for Farxiga revenue by region and a line chart for Lokelma US market share.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-b48b-74ad-8fcb-69ba4c0494fb/22",
  "deckHref": "/decks/019de071-b48b-74ad-8fcb-69ba4c0494fb",
  "deckJsonHref": "/decks/019de071-b48b-74ad-8fcb-69ba4c0494fb.json",
  "deckAnchorHref": "/decks/019de071-b48b-74ad-8fcb-69ba4c0494fb#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.1,
        "x": 0.54,
        "y": 0.73
      },
      "kind": "callout",
      "text": "Farxiga #1 innovative anti-diabetic in China and Brazil",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f710103a-fc4e-4922-a377-a1ab1cccb200",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.3,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Farxiga revenue by region (US, Europe, ERoW, EM) from Q4 2019 to Q3 2021",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "416b202d-b407-4977-9ce5-475b30ba34f8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.65,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Lokelma US branded K+ binder TRx share",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "46f4269c-1371-4bd7-a45b-503eae5953fd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.03,
        "y": 0.97
      },
      "kind": "disclaimer",
      "text": "SGLT2i = Sodium-glucose transport protein 2 inhibitor; HFrEF = Heart failure with reduced ejection fraction; K+ = potassium; TRx = total prescriptions. 1. IQVIA US monthly total prescription share data",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f58bddb7-fc9a-4fba-84d0-2943768c4146",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.35,
        "y": 0.42
      },
      "kind": "list",
      "text": "US +31%, Europe +50% and EMs +74%, boosted by HF and CKD launches; CKD approval in Europe and Japan; Updated ESC guidelines recommend Farxiga as 1st-line treatment for HFrEF",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4727ea11-33ec-433f-b2eb-7e8d2db116be",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.65,
        "y": 0.68
      },
      "kind": "list",
      "text": "Volume growth US and Japan, Europe benefitting from new launches; ESC guidelines now recommend novel K+ binders to manage hyperkalaemia",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ebf9e2a8-d472-4259-be60-3ab4675d4d4b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.4,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Total Revenue $6.0bn; growth +10%",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "06bda73e-4db7-4a9c-bc74-8bed7b375fcc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "BioPharmaceuticals: Cardiovascular, Renal and Metabolism",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d00d01ab-8538-4e13-8b38-c4d9607bdf20",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 27,
      "from": 21,
      "beatId": "20be7aa9-aa56-49cc-a307-59bd4a0f6852",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Visualization",
      "beatSlug": "monroes-sequence-visualization",
      "evidence": "The document provides a clear roadmap for the company's future growth and innovation.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}